Introduction: portal vein thrombosis is a relatively common complication of advanced
INTRODUCTION
Currently, liver transplantation represents the therapeutic strategy of choice for patients with advanced-stage liver disease. Until recently, portal vein thrombosis (PVT) was considered to be an absolute contraindication due to the sizable technical difficulties. The first successful liver transplant in a patient with these characteristics was performed in 1985 (1) and both medical and surgical approaches have changed considerably ever since. An estimated 9.7% ± 4.5% of patients undergoing liver transplantation have PVT (2), which had not been previously diagnosed in 50% of cases (3) .
Not all the mechanisms involved in the pathophysiology of PVT in cirrhotic patients are well understood. However, selected predictive factors have been described, including reduced portal flow (2) , the presence of collateral circulation (4) , prior damage to the portal vein system (5) and focal inflammatory injuries (6) . Cirrhosis-associated rebalanced hemostasis, where procoagulant factors may predominate, adds to this condition (7) (8) (9) . Approximately 43% of patients with PVT remain asymptomatic (10) and Doppler ultrasonography is the modality of choice for diagnosis. Among symptomatic patients, 39% present with gastrointestinal bleeding and 18% with abdominal pain (10) . Laboratory test results are nonspecific. However, some studies report moderate reductions in prothrombin and other coagulation factor levels, as well as increased D-dimer levels (2, (11) (12) (13) .
PVT increases technical difficulties during transplantation and requires special techniques for thrombus removal or vascular reconstruction. Longer surgery duration, greater transfusion requirements and higher surgical re-intervention rates have been reported (3, 14) . The identification of patients with PVT may condition the course of liver transplantation in that appropriate perioperative management may anticipate relevant complications. Thus, the specific goals of this study included: a) establishing the impact of PVT on the clinical course of liver transplant patients; and b) assessment of the influence of patient and liver disease-related factors on a higher incidence of PVT.
PATIENTS AND METHODS
The study included a retrospective series of 288 patients who received a liver transplant between January 2000 and December 2015 at Clínica Universidad de Navarra (Pamplona, Spain). Inclusion criteria included the presence of liver cirrhosis, age over 18 years at the time of the procedure and no prior liver transplant procedure.
Of the 288 patients included in the study, 46 (16%) had PVT. Patients with tumoral PVT were not included. The study was carried out in compliance with Good Clinical Practice standards and was approved by the Ethics Committee of Universidad de Navarra (25/10/2017).
The presence or absence of PVT was recorded preoperatively (based on imaging tests) and at the time of transplantation (intratransplant). Patients were followed up in an evolutionary manner, considering the end of the study observational period Patients with PVT identified before transplantation were managed with TIPS or lowmolecular weight heparin, at the discretion of the treating physician (15) .
Intraoperative PVT management included thrombectomy and portoportal anastomosis whenever possible. Low-molecular weight heparin was then initiated early during the postoperative period. 
Statistical analysis

RESULTS
Descriptive analysis
PVT was identified in 46 (16%) of 288 liver transplant recipients, six were females (13.8%) and 40 were males (86.2%). The PVT diagnosis was incidental in 13 cases with a tendency to statistical significance (p = 0.07). Table 2 shows the follow-up variables, including overall mortality, re-intervention rates and hemodialysis requirements.
Univariate and multivariate analysis
According to univariate analysis (Table 3) , overweight subjects or those with any degree obesity had an OR 2.1 times higher for PVT compared to subjects that were not overweight. This association was statistically significant. A significant correlation was found between the presence of varices and PVT, with a 3.7 times higher OR for PVT in comparison to cases without varices. Other factors were identified that were associated with portal thrombosis, including variceal ligation or sclerotherapy (OR = 2.3) and presence of thrombocytopenia (OR = 3.6). According to the multivariate analysis (Table 3 ) using model variables, the presence of esophageal/gastric varices (p = 0.01) and being overweight/obesity (p = 0.03) were statistically significant.
Predictive index
A predictive index was constructed to identify patients with a higher risk for PVT, where prophylactic measures may be considered. To this end, data provided by the logistic regression were used and the following formula for PVT prediction was obtained: 2 + 3 * varices + 2 * BMI + 3 * thrombocytopenia + 2 * APTT. Scores equal or above 7 were established as the cut-off for high PVT risk. The sensitivity was 76.1%, specificity was 53.7%, PPV was 23.8% and NPV was 92.2%. Data are shown in a ROC curve (Fig. 1) .
Survival analysis
Survival analysis was performed using the Kaplan-Meier method. The first follow-up date was defined as the date on which the liver transplantation was performed and the last follow-up date was defined as the date of the event (death), loss to follow-up or the end of the study follow-up. The two latter conditions were considered as censored data. The results provided by this analysis are shown in figure 2 .
A log-rank test was used to compare survival rates between the groups with and 
DISCUSSION
This study assessed the role of PVT in an ample patient cohort that underwent a liver transplantation in order to establish its predictive value, either as a standalone factor or in combination with other clinical and laboratory parameters. A significant relationship was found between BMI, the presence of pharyngeal/gastric varices, variceal ligation/sclerotherapy, thrombocytopenia and presence of PVT. However, the limitations posed in the assessment of BMI in patients with ascites must be highlighted, as this involved 2/3 of subjects in our study.
The prevalence of PVT in patients with cirrhosis varies from 4.6% to 17.9% (17) . The prevalence in our cohort was 16%, which is similar to that in the study by Koh et al. (18) . Among the cardiovascular risk factors assessed, obesity acts as a prothrombotic factor that favors chronic inflammation and impairs coagulation and fibrinolysis (19-21). In our series, patients that were overweight or obese had twice the risk of PVT compared to those with a normal weight or underweight. There was no statistically significant association between BMI and thrombotic complications in the study by Molina et al. (22) . The authors concluded that obesity does not seem to be a risk factor that reduces graft or patient survival. However, Ayala et al. demonstrated that obesity may indeed represent an independent risk factor for PVT in cirrhotic patients that are eligible for liver transplantation (23) . However, it is also associated with PVT in cases without cirrhosis (20). The higher incidence of PVT among patients with an increased BMI may be related to ascites, which also points to advanced liver disease.
Furthermore, the higher incidence of PVT seen in overweight/obese individuals may also be related to the prothrombotic tendency that is characteristic of this metabolic syndrome (24) .
Multiple clinical factors were previously associated with PVT development, including prior procedures for portal hypertension, endoscopic management of varices and thrombectomy (3). In our study, there was a statistically significant association between the presence of PVT and prior variceal ligation, with a frequency of 43.8% in this group. This association may result from an increase in thrombotic complications after surgery for portal hypertension, which most likely results from an increased inflammatory response and hampered blood flow. In fact, some studies described this as an independent risk factor (25) . With regard to liver disease complications in our cohort, patients with PVT had a higher prevalence of esophageal varices (93.5%) compared to subjects without PVT (79.3%). The presence of varices was associated with a 3-fold increase in PVT risk. A history of prior variceal bleeding increased the PVT risk by a factor of 1.9, which approached statistical significance. This association has previously been reported by Montenovo et al. (17) and may due to the presence of higher portal hypertension levels in these individuals (26) . Several studies describe a higher rate of PVT among patients with advanced liver disease, with a prevalence that ranges from < 1% for compensated cirrhosis to > 25% for decompensated disease (14, 16) . There was no differences in PVT rate among subjects with advanced liver disease in our study, although the incidence (17.8%) was consistent with the above values. In this study, the presence of PVT was not correlated with other etiologies of liver disease such as hepatitis C virus-related cirrhosis, alcoholic cirrhosis, or hepatocellular carcinoma. Even though this has been reported in previous studies (27) (28) (29) ).
An increase in transfusion requirements has been previously described for patients with PVT (27,30) due to thrombocytopenia and advanced liver disease. Our data did not substantiate this finding as there was no such increased requirement compared to patients without PVT, although this may be due to the fact that only RBC concentrates and no other blood products were factored in. With regard to laboratory parameters, there was an inverse correlation (2,31) between platelet levels and PVT. This may be due to a reduced portal flow from portal hypertension overcoming the potential "protective" effect of thrombocytopenia in the thrombosis setting. Other factors that may lead to thrombocytopenia include splenic platelet sequestration, bone marrow suppression by hepatitis C virus (HCV) and antiviral therapy with interferon (32).
A novel, interesting finding in our study was the predictive index development that included the presence of esophageal/gastric varices, BMI, the presence of thrombocytopenia and APTT. This index had an acceptable sensitivity and specificity, with a high negative predictive value. Further studies will be needed to establish its prognostic significance for PVT.
PVT had been previously described as a factor that increases mortality within 30 days post-transplant (2,30). The study by Ghabril et al. (14) that used the OPTN database found that PVT represents an independent mortality risk factor in the first 90 days post-transplant and in graft failure. Furthermore, Koh et al. (18) showed that overall survival and graft survival are similar in patients with and without PVT, which is consistent with the results obtained in the present study. Thus, survival does not seem to vary between both groups. In our series, one-year mortality was 7.1% among patients without PVT or Yerdel stage 1/2 and 42.8% in advanced stages. Of the three deceased patients, one died from persistent PVT (variceal bleeding) and one due to an increased intraoperative complexity. These results are similar to those reported by Zanetto et al. (33) in a recent meta-analysis. In this study, patients with stage 1/2 had a mortality rate of 18% within the first year, which increased to 50% for subjects with stage 3/4.
With regard to the diagnostic approach to pre-transplant PVT, we consider that all candidates for the procedure should be assessed by Doppler ultrasound. This should also be completed with angio-CT or angio-MRI scans in cases of a slow portal flow or suspected PVT, according to the recommendations issued by the Spanish Society of Liver Transplantation (SETH) (34) . We recommend anticoagulation with low molecular weight heparin for patients with partial PVT, except when contraindicated or the waiting time is short. Cases where anticoagulation is contraindicated may be considered for TIPS (15) . When thrombosis is complete or nearly complete, angio-CT should be used to assess the potential for an adequate intraoperative portal flow via large collaterals. If unfeasible, recanalization using interventional radiology may be considered (35) . The fact that advanced-stage PVT is associated with increased postoperative mortality should be borne in mind, even though it is not considered as an absolute contraindication for liver transplantation (34) .
Our research has the limitations that are typically associated with the assessment of observational data from a retrospective study. Furthermore, patient follow-up duration differs according to year of transplantation. A significant study limitation was the inability to correctly categorize PVT stage as per the classification by Yerdel et al. (16) . Furthermore, the sample size was relatively small and may interfere with the conclusions drawn from a clinical or practical perspective.
To conclude, our study identified the presence of esophageal/gastric varices and their ligation or sclerotherapy as predictive variables for PVT. Among the laboratory parameters, thrombocytopenia represents an independent risk factor for the development of PVT. Furthermore, the PVT risk doubles in overweight or obese individuals and PVT does not significantly impact on survival after liver transplantation.
The results of this study provide data with prognostic significance, although further studies are needed to establish whether a perioperative preventive/therapeutic strategy to PVT may have a significant impact on the postoperative course of liver transplantation patients. international normalized ratio; APTT: activated partial thromboplastin time. 
